

Curriculum Vitae



Personal History

First Name: Alireza

Last Name: Aliabadi

Date of Birth: 1982

Place of Birth: Iran, Southern Khorasan, Birjand

Marital Status: Married

Office Tel: 0098-831-4276481

Fax: 0098-831-4276493

E-mail: aliabadi.alireza@gmail.com

Educational History

PhD course: 2006-2010, PhD of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

PhD Thesis Topic: Synthesis and biological evaluation of 2-Phenylthiazole-4-carboxamide derivatives as apoptosis inducer via caspases pathway with potential anticancer activity.

PhD Thesis Supervisors: Pro. Dr. F. Shamsa, Pro. Dr. A. Foroumadi, Pro. Dr. S.N. Ostad

PhD Thesis Advisers: Dr J. Davoodi, Pro. Dr. A. Shafiee

PharmD course: 2000-2006, Pharmacy Doctorate (PharmD), Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.

PharmD Thesis Topic: Synthesis of 1,3,4-thiadiazole derivatives as antitubercular agents.

PharmD Thesis Supervisors: Pro. A. Foroumadi and Dr. A. H. Ebrahimabadi.

Diploma: 2000, Experimental Sciences, Nemooneh Tarbiat High School, Birjand, Iran.

Professional History

Teaching History

- 1- Teaching of medicinal chemistry, practical organic chemistry and practical instrumental analysis, Tehran, 2006-2010.
- 2- Persian and English teaching of medicinal chemistry I, II and III, Kermanshah, Since 2009.
- 3- Teaching of instrumental analysis(NMR, IR and MS spectroscopy), Kermanshah, Since 2011.
- 4- Teaching of organic chemistry I & II, Kermanshah, Since 2011.
- 5- Teaching of drug information, pharmacy practice and pharmacy internship, Kermanshah, Since 2009.
- 6- Teaching of English for pharmacy students, Kermanshah, Since 2011.
- 7- Teaching of medical terminology, Kermanshah, Since 2011.
- 8- Teaching of pharmacology for paramedical students, 2012-2015.

Practical Experiences

- ❖ Experiences and skills in organic pharmaceutical synthesis.
- ❖ Experiences in NMR, IR and MS spectra interpretation.

- ❖ Experiences in molecular modeling softwares related to drug design (MATLAB, Autodock, Arguslab, Molegro molecular viewer, Ligandscout, hyperchem, chemoffice, ligplot).
- ❖ Experiences in pharmacy practice and drug information counseling.

Academic Administrative Appointments

- **Assistant Professor** of Medicinal Chemistry, Department of Medicinal Chemistry, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Iran, 2010-2014.
- **Associate Professor** of Medicinal Chemistry, Department of Medicinal Chemistry, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Iran, 2015-2019.
- **Full Professor** of Medicinal Chemistry, Department of Medicinal Chemistry, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Iran, Since 2019.

Executive Positions and Appointments

- ❖ Head of Department of Medicinal Chemistry, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Iran, 2011-2013.
- ❖ Information Technology (IT) Manager, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Iran, 2011-2012.
- ❖ Executive manager of the *Journal of Reports in Pharmaceutical Sciences*, 2011-2012.
- ❖ Administrator of Education Development Office (EDO) of the Faculty of Pharmacy, Kermanshah University of Medical Sciences, Iran, 2013-2014.
- ❖ Dean of the educational and servicing pharmacies of the faculty of pharmacy, 2013-2014.
- ❖ Educational directorate of the faculty of pharmacy, since 2016-2019.
- ❖ Head of Department of Medicinal Chemistry, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Iran, 2017-2019.
- ❖ Dean of Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran, since 2019.

Honors & Awards:

- 1- First rank of the pharmacy basic sciences examination, March, 2003.
- 2- Elected as top student of the faculty of pharmacy, Kerman University of Medical Sciences, 2005.
- 3- Elected as intelligent student of the Medical University of Kerman, 2005.
- 4- First rank of the PhD entrance examination, March, 2006.
- 5- First rank of the specialty board examination of medicinal chemistry, Tehran University of Medical Sciences, January, 2009.
- 6- Distinguished professor in education of the faculty of pharmacy, Kermanshah University of Medical Sciences, 2011.
- 7- Distinguished researcher of the Kermanshah University of Medical Sciences, 2013.
- 8- Distinguished researcher of the Kermanshah University of Medical Sciences, 2014.
- 9- Distinguished professor in education of the Kermanshah University of Medical Sciences, 2015.
- 10- Distinguished researcher of the Kermanshah University of Medical Sciences, 2016.

Publications:

Books:

- 1- Physicians' Desk Reference, 2010.
- 2- Drug information review (Antibiotics), March 2012.
- 3- Drug information review (Cardiovascular & Respiratory agents), March 2012.
- 4- Drug information review (Gastrointestinal & Hormonal agents), March 2012.
- 5- Drug information review (Drugs affecting nervous system), under preparation.
- 6- Drug information review (Anticancer & immunomodulator agents), under preparation.
- 7- Comprehensive Textbook of Medicinal Chemistry (3 Volumes, Persian), April 2017.

Articles:

1. Ghorbani M, Zhila Izadi, Samira Jafari, Casals E, Rezaei F, **Alireza Aliabadi**, Preclinical studies conducted on nanozyme antioxidants: shortcoming and challenges based on US FDA regulations, 2021, 16(13), 1133-1151.
2. Omid Tavallaei, Milad Heidarian, Marzieh Marzbany, **Alireza Aliabadi***, Cytotoxicity and proapoptosis activity of synthetic 1,3-thiazole incorporated phthalimide derivatives on cancer cells, *Iran. J. Basic. Med. Sci.* 2021, 5, 604-614.
3. **Alireza Aliabadi**, Mina Zangeneh, Zhila Izadi, Mohammad Badzohre, Mohammad Ghadermazi, Domenica Marabello, Fereshteh Bagheri, Alireza Farokhif, Elham Motieian, Sara Abdolmaleki, Green synthesis, X-ray crystal structure, evaluation as *in vitro* cytotoxic and antibacterial agents of a new Zn(II) complex containing dipicolinic acid, *J. Mol. Struct.* 2022, 1247, 131327.
4. **Alireza Aliabadi**, Elham Motieian, Fatemeh Hosseinabadi, Mohammad Ghadermazi, Sara Abdolmaleki, One-pot synthesis, crystallographic characterization, evaluation as *in vitro* antibacterial and cytotoxic agents of two mercury(II) complexes containing pyridine dicarboxylic acid derivatives, *J. Mol. Struct.* 2021, 1226, 129405.
5. **Alireza Aliabadi**, Mohammad Hakimi, Fatemeh Hosseinabadi, Elham Motieian, Vitor Hugo Nunes Rodrigues, Mohammad Ghadermazi, Domenica Marabello, Sara Abdolmaleki, Investigation of X-ray crystal structure and *in vitro* cytotoxicity of two Ga(III) complexes containing pyridine dicarboxylic acid derivatives and 2-aminobenzimidazole, *J. Mol. Struct.* 2021, 1223, 129005.
6. Sara Abdolmaleki, Mohammad Ghadermazi, **Alireza Aliabadi**, Novel Tl(III) complexes containing pyridine-2,6-dicarboxylate derivatives with selective anticancer activity through inducing mitochondria-mediated apoptosis in A375 cells, *Sci. Rep.* 2021, 11, 15699.
7. Sara Abdolmaleki, Mohammad Ghadermazi, **Alireza Aliabadi**, Study on electrochemical behavior and *in vitro* anticancer effect of Co(II) and Zn(II) complexes containing pyridine-2,6-dicarboxylate, *Inorg. Chim. Acta* 2021, 527, 120549.
8. Rouhollah Heydari, Elham Motieian, Sara Abdolmaleki, **Alireza Aliabadi**, Mohammad Ghadermazi, Fereshteh Bagheri, and Hadi Amiri Rudbari. "Synthesis, X-ray crystal structure, thermal behavior and evaluation as an *in vitro* cytotoxic agent of a novel tin(IV) complex containing dipicolinic acid, *J. Coord. Chem.* 2020, 73, 2347–2362.
9. Rouhollah Heydari, Elham Motieian, **Alireza Aliabadi**, Sara Abdolmaleki, Mohammad Ghadermazi, Nasrin Yarmohammadi, Synthesis, crystallographic studies, electrochemical and *in vitro* cytotoxicity properties of two Mn(II) and U(IV) complexes containing dipicolinic acid and 4-dimethylaminopyridine, *Polyhedron*, 2020, 181, 114477.
10. Sara Abdolmaleki, Azade Aslani, Mohammad Ghadermazi, **Alireza Aliabadi**, Elham Motieian, Domenica Marabello, Discovery of a Ru(III) complex containing picolinate with potent inhibition effect against melanoma cell line, *J. Coord. Chem.* (Under review 2022).
11. Mina Zohrevandi, Sara Abdolmaleki, Mohammad Ghadermazi, Yasin Gholice, **Alireza Aliabadi**, Elham Motieian, Mohammad Hakimi, Domenica Marabello, *Polyhedron*, 2021, 115561.
12. **Alireza Aliabadi***, Hojat Harasami Neek, Yazdan Bahmani, 4-Halo-*N*-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)benzamide and Benzothioamide Derivatives: Synthesis and *in vitro* Anticancer Assessment, *Iran. J. Chem. Chem. Eng.* 2020, 39(5), 35-44.
13. Ahmad Mohammadi-Farani, Hosna Sadat Zamani Mousavi, **Alireza Aliabadi***, Synthesis and cytotoxicity evaluation of *N*-(5-Mercapto-4*H*-1,2,4-triazol-3-yl)-2-phenylacetamide derivatives as apoptosis inducers with potential anticancer effects, *J. Rep. Pharm. Sci.* 2020, 9(1), 128-135.
14. **Aliabadi A.***, Afzandeh N., Hosseinzadeh L., Mohammadi-Farani A., Shafiee M.H., Hanifeh Nazari H., et al., *N*-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)benzamide and benzothioamide derivatives induce apoptosis via caspase-dependent pathway, *Pharm. Chem. J.*, 2019, 53(6): 488-493.
15. Yazdan Bahmani, Tayebah Bahrami, **Alireza Aliabadi***, Synthesis, Cytotoxicity Assessment and Molecular Docking of *N*-(5-(Substituted-Benzylthio)-1,3,4-Thiadiazole-2-yl)-2-*p*-Fluorophenylacetamide Derivatives as Tyrosine Kinase Inhibitors. *Indian J. Pharm. Sci.* 2019, 81(1), 63-70.
16. Marzieh Rahmani-Khajouei, Ahmad Mohammadi-Farani, Aref Moradi, **Alireza Aliabadi***, Synthesis and evaluation of anticonvulsant activity of (*Z*)-4-(2-oxoindolin-3-ylideneamino)-*N*-phenylbenzamide derivatives in mice. *Res. Pharm. Sci.* 2018; 13(3): 262-272.
17. **Alireza Aliabadi***, Rezvan Fereidooni, Amir Kiani, Synthesis and cytotoxicity evaluation of *N*-(5-(Substituted-benzylthio)-1,3,4-thiadiazole-2-yl)-2-*p*-nitrophenylacetamide derivatives as potential anticancer agents. *Iran. J. Chem. Chem. Eng.* 2019, 38(1), 49-55.

18. **Alireza Aliabadi***, Ahmad Mohammadi-Farani, Javad Rezaei Bistouni, Synthesis and acetylcholinesterase inhibitory assessment of benzamide derivatives incorporated piperazine moiety as potential anti-alzheimer agents. *J. Pharm. Sci. Res.* Vol. 9(9), 2017, 1598-1603.
19. Ahmad Mohammadi-Farani, Leila Hosseinzadeh, Pouria Barazesh, Farahnaz Ahmadi, **Alireza Aliabadi***, Evaluation of Cytotoxicity and Apoptosis Inducing Effects of *N*-(5-mercapto-1,3,4-thiadiazol-2-yl)-2-phenylacetamide Derivatives as Caspase Enzymes Activators. *Der Pharma Chemica*, 2017, 9(17):40-45.
20. Leila Hosseinzadeh, **Alireza Aliabadi**, Mohsen Rahnama, Hamid Mir Mohammad Sadeghi, Marzieh Rahmani Khajouei, Synthesis and cytotoxic evaluation of some new 3-(2-(2-phenylthiazol-4-yl)ethyl)-quinazolin-4(3*H*) one derivatives with potential anticancer effects. *Res. Pharm. Sci.* 2017, 12(4): 290-298.
21. **Alireza Aliabadi***, Ahmad Mohammadi-Farani, Saeed Seydi-Kangarshahi, Farahnaz Ahmadi, Discovery of 2-(1,3-Dioxoisindolin-2-yl)-*N*-phenylacetamide derivatives as probable 15-lipoxygenase-1 inhibitors with potential anticancer effects. *Farmacia*, 2017, 65(2), 268-274.
22. **Alireza Aliabadi***, Ahmad Mohammadi-Farani, Mohammad Javad Ahmadvand, Marzieh Rahmani-Khajouei, Synthesis, docking and acetylcholinesterase inhibitory evaluation of (*E*)-3-(4-(diethylamino)phenyl)-1-phenylprop-2-en-1-one derivatives with probable anti-Alzheimer effects. *J. Rep. Pharm. Sci.* 2017, 6(2), 134-141.
23. Ghobad Mohammadi, Amineh Shakeri, Ali Fattahi, Pardis Mohammadi, Ali Mikaeili, **Alireza Aliabadi**, Khosro Adibkia, Preparation, physicochemical characterization and anti-fungal evaluation of nystatin-loaded PLGA-glucosamine nanoparticles. *Pharm. Res.*, 2017, (34) 301-309.
24. Marzieh Rahmani-Khajouei, Ahmad Mohammadi-Farani, Daryoush Mirzaei, **Alireza Aliabadi***, Isatin-Based Anticonvulsant Agents: Synthesis and Antiseizure Evaluation in Mice. *J. Rep. Pharm. Sci.* 2017, 6(1): 13-22.
25. Ahmad Mohammadi-Farani, Nasibeh Abdi, Alireza Moradi, **Alireza Aliabadi***, 2-(2-(4-Benzoylpiperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives: Synthesis, docking and acetylcholinesterase inhibitory evaluation as anti-Alzheimer agents. *Iran. J. Basic Med. Sci.* 2017, 20: 59-66.
26. Marzieh Rahmani-Khajouei, Ahmad Mohammadi-Farani, Mohsen Moradikhah, Javad Rezaei Bisotouni, **Alireza Aliabadi***, Synthesis and evaluation of acetylcholinesterase inhibitory effects of 2-(2-(4-benzoylpiperazin-1-yl)ethyl)-1*H*-benzo[*de*]isoquinoline-1,3(2*H*)-dione derivatives with potential anti-Alzheimer activity. *Der Pharma Chemica*, 2016, 8(18): 20-26.
27. **Alireza Aliabadi***, Ahmad Mohammadi-Farani, Sahar Roodabeh, Farahnaz Ahmadi, Synthesis and biological evaluation of *N*-(5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl)benzamide derivatives as lipoxygenase inhibitor with potential anticancer activity, *Iran. J. Pharm. Res.* 2017, 16 (1): 165-172.
28. **Alireza Aliabadi***, Ahmad Mohammadi-Farani, Maryam Azizi, Farahnaz Ahmadi, Design, synthesis and cytotoxicity evaluation of *N*-(5-benzylthio)-4*H*-1,2,4-triazol-3-yl)-4-fluorobenzamide derivatives as potential anticancer agents. *Pharm. Chem. J.* 2016, 49(10), 694-699.
29. **Alireza Aliabadi***, 1,3,4-Thiadiazole-based anticancer agents. *Anti-cancer Agent. Med. Chem.* 2016, 16(10), 1301-1314.
30. **Alireza Aliabadi***, Jino Yousefbeigi, Ahmad Mohammadi-Farani, Sahar Jamshidy Navid, Synthesis and cytotoxicity evaluation of 2-Phenyl-1*H*-benzo[*de*]isoquinoline-1,3(2*H*)-dione derivatives as apoptosis inducers with probable anticancer effects. *Int. J. Pharm. Chem.* 2016, 06 (6), 160-168.
31. Ahmad Mohammadi-Farani, Arash Haqiqi, Sahar Jamshidy Navid, **Alireza Aliabadi***, Synthesis and evaluation of LOX inhibitory activity of 2-(1,3-Dioxo-1*H*-benzo[*de*]isoquinolin-2(3*H*)-yl)-*N*-phenylacetamide derivatives. *Res. Pharm. Sci.* 2016; 11(4): 265-273.
32. Leila Hosseinzadeh, **Alireza Aliabadi**, Masoud Kalantari, Abolfazl Mostafavi, and Marzieh Rahmani Khajouei, Synthesis and cytotoxicity evaluation of some new 6-nitro derivatives of thiazole-containing 4-(3*H*)-quinazolinone. *Res. Pharm. Sci.*, 2016; 11(3): 210-218.
33. Ahmad Mohammadi-Farani, Samira Soltani Darbandi, **Alireza Aliabadi***, Synthesis and acetylcholinesterase inhibitory evaluation of 4-(1,3-Dioxoisindolin-2-yl)-*N*-

- phenylbenzamidederivatives as potential anti-alzheimer agents, *Iran. J. Pharm. Res.* 2016, 15(3), 313-320.
34. **Alireza Aliabadi***, Ahmad Mohammadi-Farani, Zeinab Hosseinzadeh, Hamid Nadri, Alireza Moradi, Farahnaz Ahmadi. Phthalimide analogs as probable 15-lipoxygenase-1 inhibitors: Synthesis, biological evaluation and docking studies, *Daru: J. Pharm. Sci.*, 2015, 23:36-43.
 35. Marzieh Rahmani-Khajouei, Ahmad Mohammadi-Farani, Hamid Ghorbani, **Alireza Aliabadi***. Synthesis and acetylcholinesterase inhibitory assessment of 3-(2-(4-benzoylpiperazin-1-yl)ethylimino)indolin-2-one with potential anti-Alzheimer effects. *J. Rep. Pharm. Sci.* 2015, 4(2), 148-157.
 36. Ahmad Mohammadi-Farani, Tayebah Bahrami, **Alireza Aliabadi***, Synthesis, docking and cytotoxicity evaluation of *N*-(5-(Benzylthio)-1,3,4-thiadiazol-2-yl)-2-(3-methoxyphenyl)acetamide derivatives as tyrosine kinase inhibitors with potential anticancer activity, *J. Rep. Pharm. Sci.* 2014, 3(2), 159-168.
 37. Ahmad Mohammadi-Farani, Alireza Foroumadi, Monireh Rezvani Kashani, **Alireza Aliabadi***, *N*-Phenyl-2-p-tolylthiazole-4-carboxamide derivatives: Synthesis and cytotoxicity evaluation as anticancer agents, *Iran J. Basic. Med. Sci.* 2014, 17:502-508.
 38. **Alireza Aliabadi***, Babak Gholamine, Tahereh Karimi, Synthesis and antiseizure evaluation of isoindoline-1,3-dionederivatives in mice, *Med. Chem. Res.*, 2014, 23, 2736-2743.
 39. Hosseinzadeh L, Khorand A, **Aliabadi A***, Discovery of 2-Phenyl-*N*-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)acetamide derivatives as apoptosis inducers via caspases pathway with potential anticancer activity, *Arch. Pharm. Chem.*, 2013,11 (346), 812-818.
 40. Lari A, Karimi I, Adibi H, **Aliabadi A**, Firoozpour L, Foroumadi A, Synthesis and in vivo psychobiological evaluation of modafinil analogs, *Daru: Journal of Pharmaceutical Sciences*, 2013,21, 67-74.
 41. **Aliabadi A***, Foroumadi A, Safavi M, K. Ardestani S, Synthesis, cytotoxicity assessment and molecular docking of 4-Substituted-2-p-tolylthiazole derivatives as probable c-Src and erb tyrosine kinase inhibitors. *Croat. Chem. Acta.* 2013, 86(3) 245-251.
 42. Foroumadi A, Mohammadi-Farani A, Garmsiri Mahvar M, **Aliabadi*A**, Synthesis and evaluation of anti-acetylcholinesterase activity of 2-(2-(4-(2-Oxo-2-phenylethyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives with potential anti-Alzheimer effects. *Iran. J. Basic Med. Sci.* 2013, 10(16), 1049-1054.
 43. **Aliabadi A***, Eghbalian E, Kiani A, Synthesis and cytotoxicity evaluation of a series of 1,3,4-thiadiazole based compounds as anticancer agents. *Iran. J. Basic Med. Sci.* 2013, 11(16), 1133-1138.
 44. Mohammadi-Farani A, Ahmadi A, Nadri H, **Aliabadi* A**, Synthesis, docking and acetylcholinesterase inhibitory assessment of 2-(2-(4-Benzylpiperazin-1-yl)ethyl)isoindoline-1,3-dione with potential anti-alzheimer effects. *Daru: J. Pharm.Sci.*, 2013, 21, 47-55.
 45. Mojarrab M, Soltani R, **Aliabadi* A**, Pyridine based chalcones: Synthesis and evaluation of antioxidant activity of 1-Phenyl-3-(pyridin-2-yl)prop-2-en-1-one derivatives. *Jundishapur J. Nat. Pharm. Prod.* 2013, 8(3), 125-130.
 46. Mohammadi-Farani A, Heidarian N, **AliabadiA***, *N*-(5-Mercapto-1,3,4-thiadiazol-2-yl)-2-phenylacetamide derivatives: Synthesis and in vitro cytotoxicity evaluation as potential anticancer agents. *Iran. J. Pharm. Res.* 2014, 12(2), 487-492.
 47. Ahmadi F, Jahangard-Yekta S, Heidari-Moghadam A, **Aliabadi A**, Application of two-layer ONIOM for studying the interaction of *N*-substituted piperazinylfluoroquinolones with ds-DNA, *Comp. Theor. Chem.* 2013, 1006, 9-18.
 48. Adibi H, Foroumadi A, Heidari O, **Aliabadi A**, Kabudanian Ardestani S, Synthesis and in vitro anti-leishmanial activity evaluation of 1-(5-halo-2-thienyl)-2-[5-(5-nitroheteroaryl)]-1,3,4-thiadiazolylthio)ethanone derivatives, *J. Rep. Pharm. Sci.*, 2012, 1(2), 73-78.
 49. **Aliabadi A***, Hasanvand Z, Kiani A, Mirabdali SS, Synthesis and in vitro cytotoxicity assessment of *N*-(5-(Benzylthio)-1,3,4-thiadiazol-2-yl)-2-(4-(trifluoromethyl)phenyl)acetamide with potential anticancer activity, *Iran. J. Pharm. Res.*, 2013, 12(4), 687-693.

50. **Aliabadi A***, Andisheh S, Tyarani-Najaran Z, Tayarani-Najaran M, 2-(4-Fluorophenyl)-*N*-phenylacetamide derivatives as anticancer agents: synthesis and in vitro cytotoxicity evaluation, *Iran. J. Pharm. Res.* 2013, 12(3), 267-271.
51. **Aliabadi A***, Mosharafi F, Tyarani-Najaran Z, Synthesis and cytotoxicity assessment of 2-(4-Fluorophenyl)-*N*-halophenylacetamide derivatives as anticancer agents, *J. Rep. Pharm. Sci.*, 2012, 1(2), 59-64.
52. Nazari Tarhan H, Hosseinzadeh L, **Aliabadi A**, Babak Gholamine, Foroumadi A, Cytotoxic and apoptogenic properties of 2-phenylthiazole-4-carboxamide derivatives in human carcinoma cell lines, *J. Rep. Pharm. Sci.* 2012, 1, 1-7.
53. **Aliabadi A***, Foroumadi A, Safavi M, Kaboudian Ardestani S, Synthesis, molecular docking and cytotoxicity evaluation of 2-(4-substituted-benzyl)isoindoline-1,3-dione derivatives as anticancer agents, *J. Rep. Pharm. Sci.* 2012, 1, 19-22.
54. **Aliabadi A**, Shamsa F, Ostad SN, Emami S, Shafiee A, Davoodi J, et al. Synthesis and biological evaluation of 2-Phenylthiazole-4-carboxamide derivatives as anticancer agents. *Eur. J. Med. Chem.* 2010, 11, 5384-5389.
55. Mahmoodi M, **Aliabadi A**, Emami S, Safavi M, Rjabalian S, Mohagheghi MA, et al. Synthesis and in vitro cytotoxicity of poly-functionalized 4-(2-arylthiazole-4-yl)-4*H*-chromenes. *Arch. Pharm. Chem.* 2010, 343, 411-416.
56. Pirali Hamedani M, Shafiee A, **Aliabadi A**, Shekarchi M, Amini M. Rouini MR, et al. A convenient method for the preparation of losartan active metabolite (EXP-3174). *Chem. Asian J.* 2009, 6, 4909-4913.
57. Letafat B, Emami S, **Aliabadi A**, Mohammadhosseini N, Moshafi MH, Asadipour A, et al. Synthesis and in vitro antibacterial activity of 5-substituted 1-Methyl-4-nitro-1*H*-imidazoles. *Arch. Pharm. Chem.* 2008, 341, 497-501.

Thesis Supervisor (PharmD):

1. **Sepehr Dadsetan**, Synthesis and cytotoxicity evaluation of 2-(5-phenylthiazol-2-yl)-1*H*-benzo[*de*]isoquinoline-1,3(2*H*)-dione derivatives as apoptosis inducers with potential anticancer effects.
2. **Sara Nazari**, Synthesis, docking and assessment of acetylcholinesterase inhibitory effects of 4-Benzamido-*N*-(1-benzylpiperidin-4-yl) benzamide derivatives with potential anti-alzheimer effects.
3. **Sadeq Bazvand**, Synthesis and cytotoxicity evaluation of Nickel and Copper complexes containing pyridine-2, 6-dicarboxylic acid as anti-cancer agents against three cell lines MCF7, HT29 and HL60.
4. **Razieh Azizifar**, Synthesis, Docking and evaluation of acetylcholinesterase inhibitory effects of 2-(2-(4-(2-oxo-2-phenylethyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives with potential anti-Alzheimer effects.
5. **Farzad Ramezani**, Synthesis and cytotoxicity evaluation of *N*-(5-mercapto-1,3,4-thiadiazol-2-yl)benzamide derivatives as potential anticancer agents.
6. **Mina Rajabian**, Synthesis, docking and acetylcholinesterase inhibitory evaluation of phthalimide and naphthalimide derivatives incorporated piperidine and piperazine moieties as potential anti-Alzheimer agents.
7. **Farzaneh Moradi**, Synthesis, docking and acetylcholinesterase inhibitory evaluation of *N*-(2-(Piperidin-1-yl)ethyl)benzamide derivatives as potential anti-alzheimer agents.
8. **Ghazal Mahmoudi**, Synthesis and cytotoxicity evaluation of 2-(4-((1,3-Dioxoisoindolin-2-yl)methyl)phenyl)-*N*-phenylthiazole-4-carboxamide derivatives as apoptosis inducers.
9. **Sanaz Sadeghi**, Synthesis, docking and acetylcholinesterase inhibitory evaluation of *N*-(1-Benzylpiperidin-4-yl)benzamide derivatives as potential anti-alzheimer agents.
10. **Niloofar Shafiee**, Synthesis and cytotoxicity evaluation of *N*-(5-Mercapto-4*H*-1,2,4-triazol-3-yl)benzamide derivatives as potential anticancer agents.
11. **Seyedeh Rana Mousavi**, Synthesis, docking and acetylcholinesterase inhibitory evaluation of 2-(2-(4-(2-phenylacetyl)piperazin-1-yl)ethyl)-1*H*-benzo[*de*]isoquinoline-1,3(2*H*)-dione derivatives as potential anti-alzheimer agents.
12. **Nasim Jalilian**, Synthesis and cytotoxicity evaluation of *N*-(5-(4-Hydroxyphenyl)thiazol-2-yl)benzamide derivatives as apoptosis inducers with potential anticancer effects.

13. **Hosna Sadat Zamani**, Synthesis and cytotoxicity evaluation of *N*-(5-Mercapto-4*H*-1,2,4-triazol-3-yl)-2-phenylacetamide derivatives as apoptosis inducers with potential anticancer effects.
14. **Elham Tahmasbi**, Synthesis and cytotoxicity evaluation of 2-(5-(Benzylthio)-4*H*-1,2,4-triazol-3-yl)-1*H*-benzo[*de*]isoquinoline-1,3(2*H*)-dione derivatives as apoptosis inducers.
15. **Narges Mirabdali**, Synthesis and cytotoxicity evaluation of *N*-(5-(benzylthio)-4*H*-1,2,4-triazol-3-yl)-2-(1,3-dioxo-1*H*-benzo[*de*]isoquinolin-2(3*H*)-yl)acetamide derivatives with potential anticancer effects.
16. **Arash Haqiqi**, Synthesis, biological evaluation and molecular docking of 2-(1,3-Dioxo-1*H*-benzo[*de*]isoquinolin-2(3*H*)-yl)-*N*-phenylacetamide derivatives as probable lipoxygenase inhibitors with potential anticancer effects.
17. **Arash Nazarpour**, Synthesis, cytotoxicity evaluation and docking of 2-(5-(1,3-Dioxoisindolin-2-yl)-1,3,4-thiadiazol-2-ylthio)-*N*-phenylacetamide derivatives as probable lipoxygenase inhibitors with potential anticancer effects.
18. **Elham Taheri**, Synthesis and antiseizure evaluation of (*Z*)-2-(2-Oxoindolin-3-ylideneamino)-*N*-phenylacetamide derivatives in mice.
19. **Mohammad Javad Ahmadvand**, Synthesis, docking and acetylcholinesterase inhibitory evaluation of (*E*)-3-(4-(diethylamino)phenyl)-1-phenylprop-2-en-1-one derivatives with probable anti-alzheimer effects.
20. **Jinoo Yosefbeigi**, Synthesis and cytotoxicity evaluation of 2-Phenyl-1*H*-benzo[*de*]isoquinoline-1,3(2*H*)-dione derivatives as apoptosis inducers with probable anticancer effects.
21. **Mohammadreza Taleb**, Synthesis and antiseizure evaluation of 2-(1,3-Dioxoisindolin-2-yl)-*N*-(2-oxo-2-phenylethyl)acetamide derivatives in mice.
22. **Milad Farjad**, Synthesis and cytotoxicity evaluation of *N*-(6-(4-chlorophenyl)-4-(pyridin-2-yl)-5,6-dihydro-2*H*-1,3-thiazin-2-yl)benzamide derivatives as apoptosis inducers with potential anticancer effects.
23. **Aram Faraji**, Synthesis, acetylcholinesterase inhibitory evaluation and docking of 2-(2-(4-Benzylpiperazin-1-yl)ethyl)-1*H*-benzo[*de*]isoquinoline-1,3(2*H*)-dione derivatives with potential anti-alzheimer effects.
24. **Javad Rezaei**, Synthesis, acetylcholinesterase inhibitory evaluation and molecular modeling of *N*-(2-(4-Benzylpiperazin-1-yl)ethyl)benzamide derivatives with probable anti-alzheimer effects.
25. **Zeinab Hosseinzadeh**, Synthesis, cytotoxicity evaluation and molecular docking of *N*-(5-(benzylthio)-1,3,4-thiadiazol-2-yl)-2-(1,3-dioxoisindolin-2-yl)acetamide derivatives as probable lipoxygenase inhibitors with potential anticancer effects.
26. **Maryam Azizi**, Design, synthesis, cytotoxicity evaluation and study of ligand-receptor interaction of *N*-(5-(Benzylthio)-4*H*-1,2,4-triazol-3-yl)-4-fluorobenzamidederivatives as tyrosine kinase inhibitor with potential anticancer effects.
27. **Tayebe Bahrami**, Design, synthesis, cytotoxicity evaluation and study of ligand-enzyme interactions of *N*-(5-(Benzylthio)-4*H*-1,2,4-triazol-3-yl)-4-methoxybenzamide derivatives as tyrosine kinase inhibitor with potential anticancer effects.
28. **Sahar Roodabeh**, Synthesis, cytotoxicity evaluation and *in silico* binding mode study of *N*-(5-(2-(3-Morpholinopropylamino)-2-oxoethylthio)-1,3,4-thiadiazol-2-yl)benzamide derivatives as lipoxygenase inhibitor with potential anticancer activity.
29. **Zeinab Mohebi**, Synthesis, acetylcholinesterase inhibitory evaluation and molecular modeling of 2-(2-(4-(2-phenylacetyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives with probable anti-alzheimer effects.
30. **Hadis Fooladi**, Synthesis, cytotoxicity evaluation and ligand-receptor interaction study of 4-Fluoro-*N*-(5-(2-oxo-2-(phenylamino)ethylthio)-1,3,4-thiadiazol-2-yl)benzamide derivatives as lipoxygenase inhibitor with potential anticancer effects.
31. **Said Seydi**, Synthesis, biological evaluation and molecular docking of 2-(1,3-Dioxoisindolin-2-yl)-*N*-phenylacetamide derivatives as probable lipoxygenase inhibitors with potential anticancer effects.
32. **Neda Heidarian**, Synthesis and cytotoxicity evaluation of *N*-(5-Mercapto-1,3,4-thiadiazol-2-yl)-2-phenylacetamide derivatives as anticancer agents.

33. **Yazdan Bahmani**, Synthesis, biological assessment and molecular study using docking method of *N*-(5-(Nitrobenzylthio)-1,3,4-thiadiazole-2-yl)-2-*p*-fluorophenylacetamide derivatives as anticancer agents.
34. **Ali Asgari**, Synthesis, cytotoxicity evaluation and drug-receptor interactions study using docking method of *N*-(5-(benzylthio)-1,3,4-thiadiazole-2-yl)-2-*p*-chlorophenylacetamide derivatives with potential anticancer effects.
35. **Sajad Andisheh**, Synthesis and cytotoxicity evaluation of 2-(4-Fluorophenyl)-*N*-nitrophenylacetamide derivatives with potential anticancer activity.
36. **Fariborz Mosharafi**, Synthesis and biological evaluation of 2-(4-Fluorophenyl)-*N*-halophenylacetamide derivatives as apoptosis inducers with probable antineoplastic effects.
37. **Zaman Hasanvand**, Synthesis, cytotoxicity evaluation and drug-receptor interactions study using docking method of *N*-(5-benzylthio)-1,3,4-thiadiazole-2-yl)-2-*p*-trifluoromethyl phenylacetamide derivatives with potential anticancer effects.
38. **Elham Eghbalian**, Design, synthesis and cytotoxicity evaluation of *N*-(5-(Benzylthio)-1,3,4-thiadiazol-2-yl)-2-(4-methoxyphenyl)acetamide derivatives as probable tyrosine kinase inhibitors with potential anticancer effects.
39. **Rezvan Fereidooni**, Design, synthesis and cytotoxicity evaluation of *N*-(5-(halobenzylthio)-1,3,4-thiadiazole-2-yl)-2-*p*-nitrophenylacetamide derivatives as probable tyrosine kinase inhibitors with potential anticancer effects.
40. **Payam Moradi**, Synthesis, biological evaluation and molecular modeling by docking method of *N*-(5-(nitrobenzylthio)-1,3,4-thiadiazole-2-yl)-*p*-bromobenzylamide derivatives as anticancer agents.
41. **Hojat Harsami Nik**, Synthesis and biological evaluation of *N*-(5-(Trifluoromethyl)-1,3,4-thiadiazol-2-yl)fluorobenzamide and benzothioamide derivatives with potential anticancer activity.
42. **Nazanin-Sadat Afnazadeh**, Synthesis and cytotoxicity evaluation of *N*-(5-(Trifluoromethyl)-1,3,4-thiadiazol-2-yl)nitrobenzamide and benzothioamide derivatives with probable anticancer activity.

Thesis Advisor(PharmD):

1. **Milad Heidarian**, Evaluation of cytotoxicity and apoptotic inducing effects of phthalimide derivatives with potential anticancer effects.
2. **Shayesteh Rezazadeh**, Evaluation of cytotoxicity and apoptotic inducing effects of phenylacetamide derivatives with potential anticancer effects.
3. **Keyhan Mohammadi**, Synthesis and biological evaluation of *N*-(2-(4-Chlorophenyl)-2-oxoethyl)-2-phenylacetamide derivatives as apoptosis inducers.
4. **Semko Nikray**, Synthesis and cytotoxicity evaluation of *N*-(5-(4-chlorophenyl)thiazol-2-yl)-2-(2-phenylacetamide derivatives with potential anticancer effects.
5. **Parsa Naderi**, Synthesis and biological evaluation of 4-(1,3-Dioxo-1*H*-benzo[*de*]isoquinolin-2(3*H*)-yl)-*N*-phenylbenzamide derivatives as apoptosis inducers.
6. **Daryoush Mirzaie**, Synthesis and antiseizure evaluation of (Z)-3-(phenylimino)indolin-2-one derivatives in mice.
7. **Aref Moradi**, Synthesis and antiseizure evaluation of (Z)-4-(2-Oxoindolin-3-ylideneamino)-*N*-phenylbenzamide in mice.
8. **Hamid Ghorbani**, Synthesis, molecular modeling and acetylcholinesterase inhibitory assessment of 3-(2-(4-benzoylpiperazin-1-yl)ethylimino)indolin-2-one with potential anti-alzheimer effects.
9. **Ali Veisi**, Synthesis and evaluation of cytotoxic effects of some new 3-(5-mercapto-1,3,4-thiadiazol-2-yl)-quinazolin-4(3*H*)-one derivatives.

10. **Mohsen Moradikhah**, Synthesis, Docking and evaluation of acetylcholinesterase inhibitory effects of 3-(2-(4-benzylpiperazin-1-yl)ethyl)-quinazolin-4(3H)-one derivatives with potential anti-Alzheimer activity.
11. **Pooria Barazesh**, Evaluation of cytotoxicity and apoptosis inducing effects of *N*-(5-Mercapto-1,3,4-thiadiazol-2-yl)-2-phenylacetamide derivatives as caspase enzymes activator.
12. **Mohammad Hossein Shafie**, Evaluation of cytotoxicity and apoptosis inducing effects of 1,3,4-thiadiazole derivatives as caspase enzymes activator.
13. **Roobeih Soltani**, Preparation and evaluation of antioxidant activity of 1-Phenyl-3-(pyridin-2-yl)prop-2-en-1-one derivatives.
14. **Aram Ahmadi**, Synthesis, molecular modeling and acetylcholinesterase inhibitory assessment of 2-(2-(4-benzylpiperazin-1-yl)ethyl)isoindoline-1,3-dione with potential anti-alzheimer effects.
15. **Elham Mohamadinezhad**, Synthesis, molecular docking and histone deacetylase inhibitory evaluation of 2-(4-(Benzyloxy)phenyl)-*N*-hydroxyacetamide derivatives as potential anticancer agents.
16. **Monireh Rezvani Kashani**, Synthesis and cytotoxicity evaluation of *N*-phenyl-2-*p*-tolylthiazole-4-carboxamide derivatives as anticancer agents.
17. **Mehdi Garmsiri Mahvar**, Synthesis, docking and evaluation of anti-acetylcholinesterase activity of 2-(2-(4-(2-Oxo-2-phenylethyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives with potential anti-alzheimer effects.
18. **Samira Soltani Darbandi**, Synthesis, molecular docking and acetylcholinesterase inhibitory evaluation of 4-(1,3-Dioxoisoindolin-2-yl)-*N*-phenylbenzamide derivatives as potential anti-alzheimer agents.
19. **Amanj Khorand**, Synthesis and cytotoxicity evaluation of 2-Phenyl-*N*-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)acetamide derivatives as apoptosis inducers with potential anticancer effects.
20. **Nasibeh Abdi**, Preparation, acetylcholinesterase inhibitory evaluation and molecular modeling of 2-(2-(4-benzoylpiperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives with probable anti-alzheimer effects.
21. **Tahereh Karimi**, Preparation and antiseizure evaluation of Isoindoline-1,3-dione derivatives in mice.
22. **Hamid Jahandoust**, Synthesis and antiseizure evaluation of 2-Benzylisoindoline-1,3-dione derivatives.
23. **Arezu Lari**, Synthesis and evaluation of new *N*-Aryl modafinil derivatives on vigilance level in albino mouse.
24. **Omid Heidari**, Synthesis and in vitro anti-leishmanial activity evaluation of 1-(5-Halo-2-thienyl)-2-[5-(5-nitroheteroaryl)]-1,3,4-thiadiazole-2-ylthio)ethanone.
25. **Hanifeh Nazari**, The effect of 2-Phenylthiazole-4-carboxamide derivatives on effector caspase-3 in T47D and HT-29 carcinoma cell lines.
26. **Sajad Jahangard Yekta**, The *in vitro* study of interaction of *N*-substituted piperazinyl fluoroquinolones with DNA by molecular modeling using DFT theory voltametric and spectroscopic methods.
27. **Neda Ebrahimi Dishabi**, The *in vitro* investigation of ofloxacin-Zn and ofloxacin-Pd complexes on cancer cells and defining a DNA-interaction model.
28. **Mohammad Reza Saberkari**, The evaluation of effects of antibacterial, cytotoxicity and in vitro study interaction of Zn-Norfloxacin, Co-Norfloxacin and Pd-Norfloxacin complexes with DNA.
29. **Amineh Shakeri**, Preparation, and physicochemical characterization of glucosamine conjugated PLGA nanoparticles for targeted delivery of nystatin against *Candida albicans*.
30. **Mansooreh Ghiasy**, Preparation, physicochemical characterization and cytotoxicity evaluation of prazosin conjugated PLGA nanoparticle for targeted delivery of flutamide to PC3 prostate cancer cells.
31. **Mostafa Fathian**, Preparation and physicochemical characterization of galactose conjugated PLGA nanoparticles for targeted delivery of amphotericin B against *Candida albicans*.

Congress Attendance and Presentation:

1. **Alireza Aliabadi**, Synthesis of 1,3,4-thiadiazole derivatives as antitubercular agents, **10th Iranian Pharmacy Students Seminar (IPSS10)**, October 2003, Mashhad, Iran.

2. Hojat Harasami Neek, **Alireza Aliabadi**, Synthesis and biological evaluation of *N*-(5-(Trifluoromethyl)-1,3,4-thiadiazol-2-yl)fluorobenzamide and benzothioamide derivatives with potential anticancer activity, **16thIranian Pharmacy Students Seminar(IPSS16)**, October 2011, Tehran, Iran.
3. Nazanin Sadat Afnanzadeh, **Alireza Aliabadi**, Synthesis and cytotoxicity evaluation of *N*-(5-(Trifluoromethyl)-1,3,4-thiadiazol-2-yl)nitrobenzamide and benzothioamide derivatives with probable anticancer activity, **16thIranian Pharmacy Students Seminar(IPSS16)**, October 2011, Tehran, Iran.
4. Ali Asgari, **Alireza Aliabadi**, Synthesis, cytotoxicity evaluation and drug-receptor interactions study using docking method of *N*-(5-(benzylthio)-1,3,4-thiadiazole-2-yl)-2-*p*-chlorophenylacetamide derivatives with potential anticancer effects, **16thIranian Pharmacy Students Seminar(IPSS16)**, October 2011, Tehran, Iran.
5. Fariborz Mosharafi, **Alireza Aliabadi**, Synthesis and biological evaluation of 2-(4-Fluorophenyl)-*N*-halophenylacetamide derivatives as apoptosis inducers with probable antineoplastic effects, **16thIranian Pharmacy Students Seminar(IPSS16)**, October 2011, Tehran, Iran.
6. Sajad Andisheh, **Alireza Aliabadi**, Synthesis and cytotoxicity evaluation of 2-(4-Fluorophenyl)-*N*-nitrophenylacetamide derivatives with potential anticancer activity, **16thIranian Pharmacy Students Seminar(IPSS16)**, October 2011, Tehran, Iran.
7. Yazdan Bahmani, **Alireza Aliabadi**, Synthesis, biological assessment and molecular study using docking method of *N*-(5-(nitrobenzylthio)-1,3,4-thiadiazole-2-yl)-2-*p*-fluorophenylacetamide derivatives as anticancer agents, **16thIranian Pharmacy Students Seminar(IPSS16)**, October 2011, Tehran, Iran.
8. Aram Ahmadi, **Alireza Aliabadi**, Synthesis, molecular modeling and acetylcholinesterase inhibitory assessment of 2-(2-(4-benzylpiperazin-1-yl)ethyl)isoindoline-1,3-dione with potential anti-alzheimer effects, **16thIranian Pharmacy Students Seminar(IPSS16)**, October 2011, Tehran, Iran.
9. Zaman Hasanvand, **Alireza Aliabadi**, Synthesis, cytotoxicity evaluation and drug-receptor interactions study using docking method of *N*-(5-benzylthio)-1,3,4-thiadiazole-2-yl)-2-*p*-trifluoromethyl phenylacetamide derivatives with potential anticancer effects, **1stMedical Students Seminar of Kermanshah University of Medical Sciences**, February 2012, Kermanshah, Iran.
10. Elham Eghbalian, **Alireza Aliabadi**, Design, synthesis and cytotoxicity evaluation of *N*-(5-(Benzylthio)-1,3,4-thiadiazol-2-yl)-2-(4-methoxyphenyl)acetamide derivatives as probable tyrosine kinase inhibitors with potential anticancer effects, **1stMedical Students Seminar of Kermanshah University of Medical Sciences**, February 2012, Kermanshah, Iran.
11. Rezvan Fereidooni, **Alireza Aliabadi**, Design, synthesis and cytotoxicity evaluation of *N*-(5-(Halobenzylthio)-1,3,4-thiadiazole-2-yl)-2-*p*-nitrophenylacetamide derivatives as probable tyrosine kinase inhibitors with potential anticancer effects, **1stMedical Students Seminar of Kermanshah University of Medical Sciences**, February 2012, Kermanshah, Iran.
12. Samira Soltani, **Alireza Aliabadi**, Synthesis, molecular modeling and acetylcholinesterase inhibitory assessment of 4-(1,3-Dioxoisindolin-2-yl)-*N*-phenylbenzamide derivatives with potential anti-alzheimer effects, **17thIranian Pharmacy Students Seminar(IPSS17)**, November 2012, Kermanshah, Iran.
13. Parisa Rohani, **Alireza Aliabadi**, Synthesis and Cytotoxicity evaluation of 2-(4-Substituted-benzyl)isoindoline-1,3-dione derivatives as anticancer agents, **17thIranian Pharmacy Students Seminar(IPSS17)**, November 2012, Kermanshah, Iran.
14. Monireh Rezvani Kashani, Synthesis and cytotoxicity evaluation of *N*-phenyl-2-*p*-tolylthiazole-4-carboxamide derivatives as anticancer agents, **17thIranian Pharmacy Students Seminar(IPSS17)**, November 2012, Kermanshah, Iran.
15. Mehdi Rahpeyma, **Alireza Aliabadi**, Synthesis and cytotoxicity assessment of 4-Substituted-2-*p*-tolylthiazole derivatives as probable anticancer agents, **17thIranian Pharmacy Students Seminar(IPSS17)**, November 2012, Kermanshah, Iran.
16. Javad Rezaei, **Alireza Aliabadi**, Payam Moradi, Synthesis and cytotoxicity evaluation of *N*-(5-(Benzylthio)-1,3,4-thiadiazol-2-yl)-2-(4-bromophenyl)acetamide derivatives as anticancer agents, **17thIranian Pharmacy Students Seminar(IPSS17)**, November 2012, Kermanshah, Iran.

17. Nasibeh Abdi, Alireza Aliabadi, Preparation, acetylcholinesterase inhibitory evaluation and molecular modeling of 2-(2-(4-benzoylpiperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives with probable anti-alzheimer effects, **17thIranian Pharmacy Students Seminar(IPSS17)**, November 2012, Kermanshah, Iran.
18. Tahereh Karimi, Alireza Aliabadi, Preparation and antiseizure evaluation of Isoindoline-1,3-dione derivatives in mice, **17thIranian Pharmacy Students Seminar(IPSS17)**, November 2012, Kermanshah, Iran.
19. Elham Mohammadinezhad, Alireza Aliabadi, Synthesis, molecular docking and histone deacetylase inhibitory evaluation of 2-(4-(Benzyloxy)phenyl)-*N*-hydroxyacetamide derivatives as potential anticancer agents, **17thIranian Pharmacy Students Seminar(IPSS17)**, November 2012, Kermanshah, Iran.
20. Mehdi Garmsiri Mahvar, Alireza Aliabadi, Synthesis, docking and evaluation of anti-acetylcholinesterase activity of 2-(2-(4-(2-Oxo-2-phenylethyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives with potential anti-alzheimer effects, **17thIranian Pharmacy Students Seminar(IPSS17)**, November 2012, Kermanshah, Iran.
21. Neda Heidarian, Alireza Aliabadi, Synthesis and cytotoxicity evaluation of *N*-(5-Mercapto-1,3,4-thiadiazol-2-yl)-2-phenylacetamide derivatives as anticancer agents, **17thIranian Pharmacy Students Seminar(IPSS17)**, November 2012, Kermanshah, Iran.
22. Amanj Khorand, Alireza Aliabadi, Synthesis and cytotoxicity evaluation of 2-Phenyl-*N*-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)acetamide derivatives as apoptosis inducers with potential anticancer effects, **17thIranian Pharmacy Students Seminar(IPSS17)**, November 2012, Kermanshah, Iran.
23. Hamid Jahandooost, Alireza Aliabadi, Synthesis and antiseizure evaluation of 2-Benzylisoindoline-1,3-dione derivatives, **17thIranian Pharmacy Students Seminar(IPSS17)**, November 2012, Kermanshah, Iran.
24. Roozbeh Soltani, Alireza Aliabadi, Synthesis and evaluation of antioxidant activity of 1-Phenyl-(3-(pyridine-2-yl)prop-2-en-1-one derivatives, **17thIranian Pharmacy Students Seminar(IPSS17)**, November 2012, Kermanshah, Iran.
25. Zeinab Hosseinzadeh, Alireza Aliabadi, Synthesis, cytotoxicity evaluation and molecular docking of *N*-(5-(benzylthio)-1,3,4-thiadiazol-2-yl)-2-(1,3-dioxoisindolin-2-yl)acetamide derivatives as probable lipoxigenase inhibitors with potential anticancer effects. **2ndMedical Students Seminar of Kermanshah University of Medical Sciences**, February 2014, Kermanshah, Iran.
26. Maryam Azizi, Alireza Aliabadi, Design, synthesis, cytotoxicity evaluation and study of ligand-receptor interaction of *N*-(5-(Benzylthio)-4*H*-1,2,4-triazol-3-yl)-4-fluorobenzamide derivatives as tyrosine kinase inhibitor with potential anticancer effects. **2ndMedical Students Seminar of Kermanshah University of Medical Sciences**, February 2014, Kermanshah, Iran.
27. Tayebe Bahrami, Alireza Aliabadi, Design, synthesis, cytotoxicity evaluation and study of ligand-enzyme interactions of *N*-(5-(Benzylthio)-4*H*-1,2,4-triazol-3-yl)-4-methoxybenzamide derivatives as tyrosine kinase inhibitor with potential anticancer effects. **2ndMedical Students Seminar of Kermanshah University of Medical Sciences**, February 2014, Kermanshah, Iran.
28. Sahar Roodabeh, Alireza Aliabadi, Synthesis, cytotoxicity evaluation and *in silico* binding mode study of *N*-(5-(2-(3-Morpholinopropylamino)-2-oxoethylthio)-1,3,4-thiadiazol-2-yl)benzamide derivatives as lipoxigenase inhibitor with potential anticancer activity. **2ndMedical Students Seminar of Kermanshah University of Medical Sciences**, February 2014, Kermanshah, Iran.
29. Zeinab Mohebi, Alireza Aliabadi, Synthesis, acetylcholinesterase inhibitory evaluation and molecular modeling of 2-(2-(4-(2-phenylacetyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives with probable anti-alzheimer effects. **2ndMedical Students Seminar of Kermanshah University of Medical Sciences**, February 2014, Kermanshah, Iran.
30. Hadis Fooladi, Alireza Aliabadi, Synthesis, cytotoxicity evaluation and ligand-receptor interaction study of 4-Fluoro-*N*-(5-(2-oxo-2-(phenylamino)ethylthio)-1,3,4-thiadiazol-2-yl)benzamide derivatives as lipoxigenase inhibitor with potential anticancer effects. **2ndMedical Students Seminar of Kermanshah University of Medical Sciences**, February 2014, Kermanshah, Iran.

31. Said Seydi, Alireza Aliabadi, Synthesis, biological evaluation and molecular docking of 2-(1,3-Dioxoisindolin-2-yl)-*N*-phenylacetamide derivatives as probable lipoxygenase inhibitors with potential anticancer effects. **2nd Medical Students Seminar of Kermanshah University of Medical Sciences**, February 2014, Kermanshah, Iran.
32. Hamid Ghorbani, Marzieh Rahmani, **Alireza Aliabadi**, Ahmad Mohammadi-Farani: Synthesis, molecular modeling and acetylcholinesterase inhibitory assessment of 3-(2-(4-benzoylpiperazin-1-yl)ethylimino)indolin-2-one with potential anti-alzheimer effects. **18th Iranian Pharmacy Students Seminar (IPSS18)**, November 2014, Tabriz, Iran.
33. Daryoush Mirzaei, Marzieh Rahmani, **Alireza Aliabadi**, Ahmad Mohammadi-Farani, Synthesis and antiseizure evaluation of (*Z*)-3-(phenylimino)indolin-2-one derivatives in mic. **18th Iranian Pharmacy Students Seminar (IPSS18)**, October 2014, Tabriz, Iran.
34. Aram Farji, **Alireza Aliabadi**, Ahmad Mohammadi-Farani, Synthesis, acetylcholinesterase inhibitory evaluation and docking of 2-(2-(4-Benzylpiperazin-1-yl)ethyl)-1*H*-benzo[*de*]isoquinoline-1,3(2*H*)-dione derivatives with potential anti-alzheimer effects. October 2014, Sari, Iran.
35. Javad Rezaei, Ahmad Mohammadi-Farani, **Alireza Aliabadi**, Synthesis, acetylcholinesterase inhibitory evaluation and molecular modeling of *N*-(2-(4-Benzylpiperazin-1-yl)ethyl)benzamide derivatives with probable anti-alzheimer effects. October 2014, Sari, Iran.

Reviewer of:

Journal:

1. Medicinal Chemistry Research
2. Archiv der Pharmazie
3. Combinatorial Chemistry & High Throughput Screening
4. Daru: Journal of Pharmaceutical Sciences
5. Research in Pharmaceutical Sciences (RPS)
6. Iranian Journal of Pharmaceutical Research (IJPR)
7. Iranian Journal of Basic Medical Sciences (IJBMS)
8. Journal of Reports in Pharmaceutical Sciences (JRPS)

Seminar:

1. 14th Iranian Pharmacy Students Seminar (IPSS14), February 2009, Ahvaz, Iran.
2. 15th Iranian Pharmacy Students Seminar (IPSS15), October 2010, Kerman, Iran.
3. 16th Iranian Pharmacy Students Seminar (IPSS16), October 2011, Tehran, Iran.
4. 1st Medical Students Seminar of Kermanshah University of Medical Sciences, February 2012, Kermanshah, Iran.
5. 17th Iranian Pharmacy Students Seminar (IPSS17), November 2012, Kermanshah, Iran.
6. 2nd Medical Students Seminar of Kermanshah University of Medical Sciences, February 2014, Kermanshah, Iran.
7. 18th Iranian Pharmacy Students Seminar (IPSS18), December 2014, Tabriz, Iran.
8. 19th Iranian Pharmacy Students Seminar (IPSS19), December 2015, Shiraz, Iran.
9. 20th Iranian Pharmacy Students Seminar (IPSS20), December 2017, Tehran, Iran.

Committees and Councils Membership:

Member of the Medical Council of Iran.

Iranian Association of Pharmaceutical Scientists (IAPS)

Scientific Interests and Goals:

Computational chemistry and molecular modeling (QSAR & Docking), drug design and organic pharmaceutical synthesis of anticancer (apoptosis inducers, caspase activators, tyrosine kinase inhibitors, lipoxygenase inhibitors), anti-alzheimer, anticovulsants and antimicrobial agents.

Language Skills:

English, Germany

